Similar articles

• Urinary screening for drugs in a hospital for the mentally subnormal.

  Ballinger BR, Simpson E, Stewart MJ. Ballinger BR, et al. Acta Psychiatr Scand. 1974;50(6):619-24. doi: 10.1111/j.1600-0447.1974.tb07525.x. Acta Psychiatr Scand. 1974. PMID: 4156151 No abstract available.
• Patterns of drug use by participants in the Western Australian methadone program, 1984-1991.

  Swensen G, Ilett KF, Dusci LJ, Hackett LP, Ong RT, Quigley AJ, Lenton S, Saker R, Caporn J. Swensen G, et al. Med J Aust. 1993 Sep 20;159(6):373-6. doi: 10.5694/j.1326-5377.1993.tb137908.x. Med J Aust. 1993. PMID: 8104312
• Thin-layer detection of pentazocine, tripelennamine, phencyclidine and propoxyphene alone or in combination with opiates in drug abuse urine screening programs.

  Kaistha KK, Tadrus R. Kaistha KK, et al. J Chromatogr. 1978 Aug 1;155(1):214-7. doi: 10.1016/s0021-9673(00)83956-4. J Chromatogr. 1978. PMID: 28334 No abstract available.
• Drug abuse screening programs: detection procedures, development costs, street-sample analysis, and field tests.

  Kaistha KK. Kaistha KK. J Pharm Sci. 1972 May;61(5):655-79. doi: 10.1002/jps.2600610502. J Pharm Sci. 1972. PMID: 4556314 Review. No abstract available.
• Methods for the analysis of morphine and related surrogates: current status.

  Mulé SJ. Mulé SJ. J Chromatogr Sci. 1974 May;12(5):245-53. doi: 10.1093/chromsci/12.5.245. J Chromatogr Sci. 1974. PMID: 4597349 Review. No abstract available.